DOI: 10.1111/apa.16624

## BRIEF REPORT

ACTA PÆDIATRICA

# Mild COVID-19 in hospitalised infants younger than 90 days

Clinical manifestations of COVID-19 are generally milder in children than adults. Severe acute respiratory distress syndrome is rarely reported, even though cardiovascular diseases, diabetes and chronic lung diseases have been associated with severe outcomes.<sup>1</sup> Children under 1 year of age are more likely to be hospitalised, but it is not clear whether this is precautionary or due to increased disease severity.<sup>2</sup> One case series found that 20 infants who tested positive for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had relatively mild infections. Two required supplementary oxygen and one needed a high-flow nasal cannula.<sup>1</sup>

This retrospective study was carried out at the Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy. We reviewed the clinical charts of all infants under 90 days of age who presented to our paediatric emergency department (PED) from 1 February 2020 to 28 February 2022. We tested symptomatic patients who presented to the PED using nasopharyngeal polymerase chain reaction tests from 1 February 2020. From March 2021, only symptomatic patients who were hospitalised were tested. We compared the clinical outcomes of infants who tested positive and negative by collecting various data from their medical records (Table 1).

Fisher's exact test was used to compare categorical variables. A two-sided p value of less than 0.05 was considered statistically significant.

The Institutional Review Board approved the study and the parents or legal guardians provided informed consent. During the study period 1260 infants under 90 days of life presented to the PED with acute illnesses. We excluded 1101 who were not hospitalised and 20 without parental consent. This means that 139 infants were hospitalised and included in the study and 29 (21%) tested positive for SARS-CoV-2. Six infants who tested negative had associated diseases or comorbidities: four had congenital heart disease, one had Down syndrome, two had congenital anomalies of the kidney and urinary tract and two had congenital cytomegalovirus infections. None of the positive infants had associated conditions. Table 1 summarises the main characteristics of the population.

Virus positive infants presented more frequently with fever than those who tested negative (66% versus 27%, p = 0.0001). None of the 11 subjects who appeared to be ill tested positive and three were diagnosed with bronchiolitis. We found that 31/110 who tested negative were admitted to the intensive care unit, including seven who had bronchiolitis. Nasal swabs were positive for the respiratory syncytial virus in 18/30 cases of bronchiolitis. One virus positive patient was not included in the study. He presented with fever and a urinary tract infection, was hospitalised for 36 h, took oral antibiotics and was discharged home. We also noted that 10 of the 110 infants who tested negative were hospitalised and needed respiratory support. None of those who tested positive required this support. One who tested negative required continuous positive airway pressure and one required oxygen. Another patient who tested negative had an unscheduled visit to the PED with new symptoms, namely cough and rhinitis 7 days after discharge, but was not hospitalised.

To our knowledge, this was the largest case series of COVID-19 in infants under 90 days of age and it provides additional evidence that COVID-19 is mild disease in this age group, with better clinical outcomes than infants with other acute illnesses. Few severe COVID-19 cases have been reported under 90 days of age, with some cases of respiratory distress. All the virus positive infants in our study appeared well and did not have severe disease or require intensive care or respiratory support. The most frequent symptom was fever, followed by respiratory symptoms, such as a cough and mild breathing difficulties, as previously reported.<sup>3</sup> None of the virus positive infants developed bronchiolitis, in line with other data.<sup>4</sup> In fact, infants in the virus negative group were more likely to need intensive care for bronchiolitis and the respiratory syncytial virus, despite the dramatic decreases in these during the first year of the pandemic.<sup>5</sup>

Our study had some limitations. It was retrospective and monocentric and our findings may not be generalisable to other settings, such as low-income countries. Also, until February 2021 all infants with symptoms that suggested SARS-CoV-2 infections were tested, but from March 2021 only patients who were hospitalised were tested. Finally, none of the infants who tested positive had associated diseases or comorbidities and we were not able to analyse whether underlying conditions had an impact on clinical outcomes.

In conclusion, this study showed that COVID-19 was milder in infants than viral bronchiolitis and other acute illnesses, suggesting that precautionary hospitalisation of infants who do not appear ill is not necessary. According to this preliminary evidence, such infants under 90 days of age could be treated the same as those with any other viral infections and be discharged to a reliable family, with adequate follow-up. More data are needed to confirm these results.

© 2022 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd

Abbreviations: PED, paediatric emergency department; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

2

-WILEY- ACTA PÆDIATRICA

Positive for ARS-CoV-2 (A = 29)Negative for SARS-CoV-2 (A = 2000-2000-2000-2000-2000-2000-2000-20	I NURTURING THE C	HILD		
F16 (55%)53 (48%)0.64M13 (45%)57 (52%)Triage code103 (2%)Triage code203 (2%)103 (2%)0.6420 (31%)46 (42%)030 (31%)46 (42%)0403 (2%)0.001Mapeared ill0011 (0%)0.16Symptoms5555Fever19 (6%)30 (27%)0.0010.16Cough and rhinitis9 (31%)30 (27%)0.160Cough and rhinitis0 (13%)10 (3%)0.220Vorniting1 (3%)10 (3%)0.210Vorniting0 (0%)6 (5%)NA0Others0 (10%)10 (3%)0.0020Others0 (10%)10 (3%)0.0020Median length of hospitalisation (days)10 (3%)10 (3%)10Median length of hospitalisation (days)2 (13%)10 (3%)10 (3%)PICU/ NCU03 (12%)10 (3%)10 (3%)10 (3%)PICU/ NCU010 (3%)10 (3%)10 (3%)10 (3%)Picular langtons , f(%)2 (21%)2 (21%)10 (3%)10 (3%)Picular langton fraction10 (3%)10 (3%)10 (3%)10 (3%)Picular langton fraction3 (23%)10 (3%)10 (3%)10 (3%)Picular langton fraction3 (23%)10 (3%)10 (3%)10 (3%)<		SARS-CoV-2	SARS-CoV-2	p values
M         13 (45%)         57 (52%)           On-admission         Triage code         1         0         3 (2%)         0.36           1         0         3 (2%)         0.36         20 (69%)         59 (54%)           3         9 (31%)         46 (42%)         4         0         3 (2%)           Appeared ill         0         11 (10%)         0.16           Symptoms         11 (10%)         0.0001         0.0001           Cough and rhinitis         9 (31%)         30 (27%)         0.0001           Cough and rhinitis         9 (31%)         30 (27%)         0.16           Respiratory distress         4 (14%)         18 (16%)         0.21           Vomiting         1 (3%)         10 (9%)         0.22           Irritability         0 (0%)         6 (5%)         NA           Others         6 (21%)         10 (9%)         0.22           Irritability         0 (0%)         12 (13%)         0.09           Clinical outcomes         1         1           PICU/NICU         0         31 (28%)         0.0031           PED (OBI)         27 (93%)         71 (65%)         0.0024           PED (OBI)         29 (21%)	Sex			
M13(45%)57(52%)Initiage codeTriage code103(2%)0.36220(69%)3(2%)0.3639(31%)46(42%)03(2%)403(2%)0.16Appeared ill03(2%)0.0001Symptoms11(10%)0.1630(27%)0.0011Cough and rhinitis9(31%)30(27%)0.16Respiratory distress4 (14%)30(27%)0.16Vomiting1(3%)10(9%)0.22Irritability0(0%)6 (5%)NAOthers6 (21%)10(9%)0.021Others011%)0.12Median length of hospitalisation (day)11Median length of hospitalisation (day)10(9%)0.12Arbitotic therapy010(9%)0.12PICUNICU031(28%)0.0031PICUNICU031(28%)1PICUNICU27(93%)14(5%)0.0032PICUNICU29(1%)11PICUNICU29(21%)11PICUNICU29(21%)11PICUNICU29(21%)11PICUNICU29(21%)11PICUNICU29(21%)11PICUNICU29(21%)11PICUNICU29(21%)11PICUNICU29(21%)11PICUNICU29(21%)11PICUNICU20(	F	16 (55%)	53 (48%)	0.64
Triage code103 (2%)0.36220 (9%)59 (54%)39 (31%)46 (42%)403 (2%)Append ill010 (2%)Fever oll9 (31%)30 (27%)0.0001Cough and rhinitis9 (31%)30 (27%)0.16Cough and rhinitis9 (31%)30 (27%)0.16Respiratory distress4 (14%)18 (16%)0.21Voniting13%10 (9%)0.22Irritability00%16 (5%)NAOthers6 (21%)12 (11%)0.09Others6 (21%)12 (11%)0.12Median length of hospitalisation (day)11Antibotic therapy010 (9%)0.12PICU/NICU031 (28%)0.0031PED (DBI)27 (93%)71 (65%)0.0024PED (DBI)29 (21%)11Furdiandentified10 (22%)11PICUNICU13 (33%)11PICUNICU29 (21%)11Furdiandentified30 (22%)11PICUDI-1929 (21%)11Funchiolitis30 (22%)11Inary tract infection11 (8%)11Inary tract infection13 (3%)11Inary tract infection13 (3%)11Inary tract infection13 (3%)11Inary tract infection13 (3%)11Inary trac	М	13 (45%)	57 (52%)	
103(2%)0.36220(69%)59 (54%)39 (31%)46 (42%)403(2%)Appeared ill011 (10%)0.16Symptoms11 (10%)0.00010.001Cough and rhinitis9 (31%)30 (27%)0.0001Cough and rhinitis9 (31%)30 (27%)0.16Respiratory distress4 (14%)18 (16%)0.21Vomiting1 (3%)10 (9%)0.22Irritability0 (0%)6 (5%)NAOthers6 (21%)10 (9%)0.09Others0 110 (9%)0.12Antibotic therapy111Vard admitted to11 (15%)0.78PICU/NICU031 (28%)0.0033PED (OBI)27 (93%)71 (65%)0.0024Bronchiolitis30 (22%)11Furdiansens, n (%)22 (13%)11Urinary tract infection18 (13%)11Infaction time21 (16%)11Infaction time11 (8%)11Infaction time30 (22%)11Infaction time13 (3%)11Infaction time30 (22%)11Infaction time30 (22%)11Infaction time30 (22%)11Infaction time30 (22%)11Infaction time30 (22%)11Infaction time30 (22%)1<	On admission			
2 $20 (69\%)$ $5^{4}$ 3 $9(31\%)$ $46 (42\%)$ 4 $0$ $3 (2\%)$ Appeared ill $0$ $11 (10\%)$ $0.16$ Symptoms $11 (10\%)$ $0.0001$ Fever $19 (66\%)$ $30 (27\%)$ $0.0001$ Cough and rhinitis $9 (31\%)$ $30 (27\%)$ $0.16$ Respiratory distress $4 (14\%)$ $18 (16\%)$ $0.221$ Vomiting $1 (3\%)$ $10 (9\%)$ $0.22$ Irritability $0 (0\%)$ $6 (5\%)$ NA         Others $6 (21\%)$ $10 (9\%)$ $0.22$ Irritability $0 (0\%)$ $6 (5\%)$ NA         Others $6 (21\%)$ $10 (9\%)$ $0.12$ Antibiotic therapy $0$ $10 (9\%)$ $0.12$ Antibiotic therapy $2 (17\%)$ $0.78$ $0.0024$ PICU/NICU $0$ $31 (28\%)$ $0.0024$ General ward $2 (79\%)$ $8 (7\%)$ $1$ Fourieral ward $30 (22\%)$ $10 (9\%)$ $10 (9\%)$ Image (10) <t< td=""><td>Triage code</td><td></td><td></td><td></td></t<>	Triage code			
3         9 (31%)         46 (42%)           4         0         3 (2%)           Appeared ill         0         11 (10%)         0.16           Symptoms         11 (10%)         0.0001         0.0001           Cough and rhinitis         9 (31%)         30 (27%)         0.0001           Cough and rhinitis         9 (31%)         30 (27%)         0.16           Respiratory distress         4 (14%)         18 (16%)         0.21           Vomiting         1 (3%)         10 (9%)         0.22           Irritability         0 (0%)         6 (5%)         NA           Others         6 (21%)         12 (11%)         0.09           Clinical outcomes         1         1         1           Respiratory support*         0         10 (9%)         0.12           Antibiotic therapy         5 (17%)         17 (15%)         0.78           Vard admitted to         27(93%)         12 (13%)         0.0024           PEQ (OBI)         27 (93%)         14 (5%)         0.024           Bronchiolitis         30 (22%)         1         1           Urinary tract infection         18 (13%)         1         1           Urinary tract infection	1	0	3 (2%)	0.36
4         0         3 (2%)           Appeared ill         0         11 (10%)         0.16           Symptoms         -         -         -           Fever         19 (66%)         30 (27%)         0.0001           Cough and rhinitis         9 (31%)         30 (27%)         0.16           Respiratory distress         4 (14%)         18 (16%)         0.21           Vomiting         1 (3%)         10 (9%)         0.22           Irritability         0 (0%)         6 (5%)         NA           Others         6 (21%)         12 (11%)         0.09           Clinical outcomes         12 (11%)         0.09         0.12           Median length of hospitalisation (days)         1         1         1           Respiratory support <sup>a</sup> 0         10 (9%)         0.12           Antibiotic therapy         5 (17%)         17 (15%)         0.78           Vard admitted to         27 (93%)         31 (28%)         0.0024           PED (OBI)         27 (93%)         165%)         0.0024           General ward         2 (7%)         8 (7%)         1           Final diagnosis, n (%)         1         1         1           Upper res	2	20 (69%)	59 (54%)	
Appeared ill         0         11 (10%)         0.16           Symptoms         -	3	9 (31%)	46 (42%)	
Symptoms         Fever         19 (66%)         30 (27%)         0.0001           Cough and rhinitis         9 (31%)         30 (27%)         0.16           Respiratory distress         4 (14%)         18 (16%)         0.21           Vomiting         1 (3%)         10 (9%)         0.22           Irritability         0 (0%)         6 (5%)         NA           Others         6 (21%)         12 (11%)         0.09           Clinical outcomes         1         1         1           Respiratory support*         0         10 (9%)         0.12           Antibiotic therapy         5 (17%)         17 (15%)         0.78           Vard admitted to         27 (93%)         71 (65%)         0.0033           PED (OBI)         27 (93%)         71 (65%)         0.0024           General ward         29 (21%)         1         1           Final diagnosis, n (%)         27 (93%)         71 (65%)         0.0024           Igen respiratory tract infection         18 (13%)         1         1           Final diagnosis, n (%)         29 (21%)         1         1         1           Image: CoviD-19         29 (21%)         1         1         1           I	4	0	3 (2%)	
Fever19 (66%)30 (27%)0.0001Cough and rhinitis9 (31%)30 (27%)0.16Respiratory distress4 (14%)18 (16%)0.21Vomiting1 (3%)10 (9%)0.22Irritability0 (0%)6 (5%)NAOthers6 (21%)12 (11%)0.09Others6 (21%)12 (11%)0.09Median length of hospitalisation (days)11Respiratory support <sup>a</sup> 010 (9%)0.12Antibiotic therapy5 (17%)17 (15%)0.78Vard admitted to5 (17%)17 (15%)0.0003PICU/NICU031 (28%)0.0003PED (OBI)27 (93%)71 (65%)0.0024General ward2 (7%)8 (7%)1FOVID-1929 (21%)5 (17%)1Bronchiolitis30 (22%)5 (16%)5 (16%)Upper respiratory tract infection18 (13%)5 (16%)Upper respiratory tract infection18 (13%)5 (16%)Fever of unknown origin8 (6%)5 (3%)Gastroenteritis4 (3%)5 (2%)	Appeared ill	0	11 (10%)	0.16
Cough and rhinitis9(31%)30(27%)0.16Respiratory distress4(14%)18(16%)0.21Voniting1(3%)10(9%)0.22Iritability0(0%)6(5%)NAOthers6(21%)12(11%)0.09Uters6(21%)12(11%)0.09Median length of hospitalisation (day)11Respiratory support*010(9%)0.12Antibiotic therapy017310(9%)0.12PICU/NICU010(9%)0.003PED (OBI)27(93%)71(65%)0.0024General ward20%)11(8%)1FOVID-1903(22%)11Picoriolitis30(22%)11Imagination for the spiratory or the spiratory	Symptoms			
Respiratory distress4 (14%)18 (16%)0.21Vomiting1 (3%)10 (9%)0.22Irritability0 (0%)6 (5%)NAOthers6 (21%)12 (11%)0.09Jutters5 (21%)12 (11%)0.09K= Juters111R=spiratory support <sup>a</sup> 010 (9%)0.12Antibiotic therapy5 (17%)17 (15%)0.78PICU/NICU031 (28%)0.003PED (OBI)27 (93%)71 (65%)0.0024Q=neral ward20%)140.003Forchiolitis30 (22%)11Iupper respiratory tract infection18 (13%)1Iupper respiratory tract infection16 (3%)1Iupper respiratory tract infection6 (6%)1Iupper respiratory tract infection6 (3%)1Iupper respiratory tract infection6 (3%)1Iupper respiratory tract infection8 (3%)1Iupper respiratory tract infection9 (3%)1Iupper r	Fever	19 (66%)	30 (27%)	0.0001
Vomiting1 (3%)10 (9%)0.22Irritability0 (0%)6 (5%)NAOthers6 (21%)12 (11%)0.09Clinical outcomes111Respiratory support*010 (9%)0.12Antibiotic therapy5 (17%)17 (15%)0.78PICU/NICU031 (28%)0.0033PED (OBI)27 (93%)71 (65%)0.0024General ward27%)8 (7%)1Fortholitis30 (22%)11Upper respiratory tract infection18 (13%)1Upper respiratory origin8 (6%)11Gastroenteritis4 (3%)2(%)1	Cough and rhinitis	9 (31%)	30 (27%)	0.16
Irritability0 (0%)6 (5%)NAOthers0 (21%)12 (11%)0.09Clinical outcomes112 (11%)0.09Median length of hospitalisation (days)111Respiratory support*010 (9%)0.12Antibiotic therapy5 (17%)17 (15%)0.78Vard admitted to17 (15%)0.00330.0033PED (OBI)027 (93%)71 (65%)0.0024General ward29 (21%)11FOVID-1929 (21%)11Bronchiolitis30 (22%)11Upper respiratory tract infection18 (13%)11I (astroenteritis4 (3%)11Acute otilis media30 (22%)11	Respiratory distress	4 (14%)	18 (16%)	0.21
Others6 (21%)12 (11%)0.09Clinical outcomesMedian length of hospitalisation (days)11Respiratory support*010 (9%)0.12Antibiotic therapy5 (17%)17 (15%)0.78PICU/NICU031 (28%)0.0003PED (OBI)27 (93%)71 (65%)0.0024General ward207%)8 (7%)1VSCVID-1929 (21%)1Poper respiratory tract infection18 (13%)1Upper respiratory tract infection18 (3%)1Fover of unknown origin8 (6%)1Acute otilis media30 (22%)1	Vomiting	1 (3%)	10 (9%)	0.22
Clinical outcomesMedian length of hospitalisation (days)11Respiratory support <sup>a</sup> 010 (9%)0.12Antibiotic therapy5 (17%)17 (15%)0.78Vard admitted to517 (15%)0.78PICU/NICU031 (28%)0.0003PED (OBI)27 (93%)71 (65%)0.0024General ward2(7%)8 (7%)1For Idiagnosis, n (%)29 (21%)1Fornchiolitis30 (22%)1Jopper respiratory tract infection18 (13%)1I Urinary tract infection11 (8%)1Fever of unknown origin8 (6%)1Gastroenteritis3 (2%)1	Irritability	0 (0%)	6 (5%)	NA
Median length of hospitalisation (day)11Respiratory support®010 (9%)0.12Antibiotic therapy5 (17%)17 (15%)0.78PICU/NICU031 (28%)0.0003PED (OBI)27 (93%)71 (65%)0.0024General ward27(%)8 (7%)1FUTUPI92 (11%)11FURDIPI92 (21%)11Image: Sing (%)30 (22%)11Image: Sing (%)18 (13%)11Image: Sing (%)11 (8%)11Image: Sing (%)11 (8%)11Image: Sing (%)11 (8%)11Image: Sing (%)16 (3%)11Image: Sing (%)13 (3%)11Image:	Others	6 (21%)	12 (11%)	0.09
Respiratory support®010 (9%)0.12Antibiotic therapy5 (17%)17 (15%)0.78PICU/NICU031 (28%)0.003PED (OBI)27 (93%)71 (65%)0.0024General ward27(%)8 (7%)10FUOVID-1929 (21%)YYPonchiolitis30 (22%)YYUpper respiratory tract infection18 (13%)YYFover of unknown origin8 (6%)YYGastroenteritis4 (3%)YYAcute otitis media30 (22%)YY	Clinical outcomes			
Antibiotic therapy5 (17%)17 (15%)0.78PICU/NICU031 (28%)0.0003PED (OBI)27 (93%)71 (65%)0.0024General ward27%)8 (7%)1FUCU/D1929 (21%)	Median length of hospitalisation (days)	1	1	
Ward admitted to       PICU/NICU       0       31 (28%)       0.0003         PED (OBI)       27 (93%)       71 (65%)       0.0024         General ward       2 (7%)       8 (7%)       1         Final diagnosis, n (%)         COVID-19       29 (21%)	Respiratory support <sup>a</sup>	0	10 (9%)	0.12
PICU/NICU031 (28%)0.0033PED (OBI)27 (93%)71 (65%)0.0024General ward2(7%)8 (7%)1FUTURE92 (21%)92 (21%)92 (21%)Ponchiolitis30 (22%)92 (21%)92 (21%)Image: Properties of the strengt of the	Antibiotic therapy	5 (17%)	17 (15%)	0.78
PED (OBI)       27 (93%)       71 (65%)       0.0024         General ward       2 (7%)       8 (7%)       1         Formation of the second secon	Ward admitted to			
General ward2 (7%)8 (7%)1Final diagnosis, n (%)29 (21%)29 (21%)1Ponchiolitis30 (22%)11Upper respiratory tract infection18 (13%)11Fover of unknown origin8 (6%)11Gastroenteritis4 (3%)11Acute otitis media3 (2%)11	PICU/NICU	0	31 (28%)	0.0003
Final diagnosis, n (%)COVID-1929 (21%)Bronchiolitis30 (22%)Upper respiratory tract infection18 (13%)Urinary tract infection11 (8%)Fever of unknown origin8 (6%)Gastroenteritis4 (3%)Acute otitis media3 (2%)	PED (OBI)	27 (93%)	71 (65%)	0.0024
COVID-1929 (21%)Bronchiolitis30 (22%)Upper respiratory tract infection18 (13%)Urinary tract infection11 (8%)Fever of unknown origin8 (6%)Gastroenteritis4 (3%)Acute otitis media3 (2%)	General ward	2 (7%)	8 (7%)	1
Bronchiolitis30 (22%)Upper respiratory tract infection18 (13%)Urinary tract infection11 (8%)Fever of unknown origin8 (6%)Gastroenteritis4 (3%)Acute otitis media3 (2%)	Final diagnosis, n (%)			
Upper respiratory tract infection18 (13%)Urinary tract infection11 (8%)Fever of unknown origin8 (6%)Gastroenteritis4 (3%)Acute otitis media3 (2%)	COVID-19	29 (21%)		
Urinary tract infection11 (8%)Fever of unknown origin8 (6%)Gastroenteritis4 (3%)Acute otitis media3 (2%)	Bronchiolitis	30 (22%)		
Fever of unknown origin8 (6%)Gastroenteritis4 (3%)Acute otitis media3 (2%)	Upper respiratory tract infection	18 (13%)		
Gastroenteritis4 (3%)Acute otitis media3 (2%)	Urinary tract infection	11 (8%)		
Acute otitis media 3 (2%)	Fever of unknown origin	8 (6%)		
	Gastroenteritis	4 (3%)		
Other 36 (26%)	Acute otitis media	3 (2%)		
	Other	36 (26%)		

TABLE 1 Characteristics and outcomes of the 139 study subjects

Abbreviations: NICU, neonatal intensive care unit; OBI, brief intensive observation; PICU, paediatric intensive care unit; PED, paediatric emergency department.

<sup>a</sup>Respiratory support: oxygen, high-flow nasal cannula, continuous positive airway pressure.

# CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

Alessia Giuseppina Servidio<sup>1</sup> Giacomo Visentin<sup>1</sup> Rosaura Conti<sup>1</sup> 💿 Giorgio Cozzi<sup>2</sup> Laura Travan<sup>2</sup>

Jenny Bua<sup>2</sup> Egidio Barbi<sup>1,2</sup> 🕩 Alessandro Amaddeo<sup>2</sup>

<sup>1</sup>Department of Medicine, Surgery, and Health Sciences, University of Trieste, Trieste, Italy <sup>2</sup>Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy

ACTA PÆDIATRIC

#### Correspondence

Alessia Giuseppina Servidio, Department of Medicine, Surgery, and Health Sciences, University of Trieste, Trieste, Italy. Email: servidioalessiag@gmail.com

# ORCID

Alessia Giuseppina Servidio <sup>®</sup> https://orcid. org/0000-0001-7421-0703 Rosaura Conti <sup>®</sup> https://orcid.org/0000-0002-5312-2090 Egidio Barbi <sup>®</sup> https://orcid.org/0000-0002-6343-846X

### REFERENCES

1. Leibowitz J, Krief W, Barone S, et al. Comparison of clinical and epidemiologic characteristics of young febrile infants with and

without severe acute respiratory syndrome Coronavirus-2 infection. J Pediatr. 2021;229:41-47.

- Hause AM, Baggs J, Marquez P, et al. COVID-19 vaccine safety in children aged 5–11 years – United States, November 3–December 19, 202. Morbidity Mortality Weekly Rep. 2021;70:32.
- Bellini T, Rotulo GA, Caruggi S, Carta S, Bonato I, Piccotti E. Characteristics of COVID-19 patients up to 6 months of age admitted to a paediatric emergency department. Acta Paediatr. 2022;111:272-274.
- 4. Cozzi G, Cortellazzo Wiel L, Amaddeo A, et al. Prevalence of SARS-CoV-2 positivity in infants with bronchiolitis: a multicentre international study. Arch Dis Child. 2022;107:840-844.
- Amaddeo A, Cason C, Cozzi G, Ronfani L, Comar M. Social distancing measures for COVID-19 are changing winter season. Arch Dis Child. 2021;106:e47.

-WILEY